XML 37 R27.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2025 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Christopher Mutz [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On June 16, 2025, Christopher Mutz, Senior Vice President, Head of Rare Disease of the Company, adopted a Rule 10b5-1 trading plan. Mr. Mutz’s Rule 10b5-1 trading plan provides for a term commencing on January 7, 2026 and ending on March 20, 2026 and for the sale of up to (i) 4,019 shares of the common stock of the Company, (ii) up to 21,717 shares of common stock upon the vesting of certain RSAs, subject to reduction for shares withheld by the Company to satisfy tax withholding obligations and (iii) up to 5,789 shares of common stock upon the vesting of certain PSUs, subject to the satisfaction of certain performance conditions and reduction for shares withheld by the Company to satisfy tax withholding obligations.
Name	Christopher Mutz
Title	Senior Vice President, Head of Rare Disease
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 16, 2025
Expiration Date	March 20, 2026
Arrangement Duration	277 days
Trading Arrangement, Common Stock [Member] \| Christopher Mutz [Member]
Trading Arrangements, by Individual
Aggregate Available	4,019
Trading Arrangement, Restricted Stock Awards [Member] \| Christopher Mutz [Member]
Trading Arrangements, by Individual
Aggregate Available	21,717
Trading Arrangement, Performance Stock Units [Member] \| Christopher Mutz [Member]
Trading Arrangements, by Individual
Aggregate Available	5,789